Research & Development
Vanda Pharmaceuticals reports positive EMA opinion on orphan drug designation for imsidolimab in generalised pustular psoriasis
17 July 2026 - US pharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Thursday that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopt...
World Health Organization approves 'codabakalner' as International Nonproprietary Name for Spinogenix's SPG601
17 July 2026 - Clinical-stage biopharmaceutical company Spinogenix Inc announced on Thursday that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization has app...
Lakewood-Amedex Biotherapeutics reports positive Nu-3 Gel preclinical safety data for upcoming Phase 2a trial
16 July 2026 - Clinical-stage biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT) on Wednesday announced preclinical safety data for its Nu-3 gel formulation that establishes a str...
MAXONA Pharmaceuticals' Phase 2 clinical trial IND application for MAX-001 cleared by US FDA
16 July 2026 - Clinical-stage pharmaceutical company MAXONA Pharmaceuticals announced on Wednesday that the US Food and Drug Administration (FDA) has cleared the company's Investigational New Dru...
FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy
15 July 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has granted priority re...
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
14 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Tuesday that it has agreed an exclusive worldwide licence with China's Dizal Pharmaceutical C...
Related Headlines

European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC

US FDA accepts BioMarin's sNDA for full approval of VOXZOGO (vosoritide) for children with achondroplasia

Eisai reports new data showing etalanetug reduces Alzheimer's Disease tau tangle‑specific biomarker

FDA approves Sanofi's subcutaneous Sarclisa Escena as first anticancer therapy delivered via on-body injector

Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA

BiBBInstruments signs first European distribution deal for EndoDrill GI with Palex Spain

Vector Science and Therapeutics names Darryl Drake Jr. president of Valor athlete and performance division

Invictus Pharmacy and Mullan Pharmaceutical partner to expand patient access to Ganirelix Acetate Injection

Vanda Pharmaceuticals' investigational therapy for Charcot-Marie-Tooth disease type 2S granted FDA Rare Pediatric Disease Designation

Ascletis submits two IND applications to US FDA for obesity treatments

AbbVie's TEPKINLY (epcoritamab) combination approved in Europe to treat relapsed or refractory follicular lymphoma

AMO Pharma updates on scientific advice for AMO-02 registrational clinical study in congenital myotonic dystrophy type 1

IceCure reports growing adoption of ProSense cryoablation in Brazil

Aurinia initiates PRESERVE Phase 4 study of LUPKYNIS combination therapy in lupus nephritis

Data from Partner Therapeutics' eNRGy trial of zenocutuzumab published in Journal of Clinical Oncology